Agonistas de los receptores de tipo Toll como terapias contra el cáncer: una revisión de patentes (2014-2024)
Video Experimental Relacionado
Updated: Sep 8, 2025
07:36
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
5.4K
Pankaj Kumar1, Zahid Bashir Zargar1, Kanwaljit Chopra1
1University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Expert opinion on therapeutic patents
|September 5, 2025
Resumen
Los agonistas del receptor Toll-like (TLR) son prometedores en la inmunoterapia del cáncer al estimular las respuestas inmunes contra los tumores. Las patentes recientes destacan su potencial para mejorar la eficacia del tratamiento y reducir los efectos secundarios, a pesar de los desafíos como los eventos adversos.
Área de la Ciencia:
- Inmunología
- En el campo de la oncología
- Farmacología
Sus antecedentes:
- Los receptores de tipo Toll (TLR) son cruciales en la inmunoterapia del cáncer, ya que modulan las respuestas inmunes contra los tumores.
- Los TLR específicos (TLR3, TLR4, TLR7, TLR8, TLR9) se investigan por su papel en el aumento del reconocimiento del tumor y la eficacia del tratamiento.
- Los TLR activan las citoquinas proinflamatorias, promoviendo la inmunidad antitumoral a través de la activación de las células T y la maduración de las células dendríticas.
Objetivo del estudio:
- Revisar las patentes de 2014 a 2024 sobre las estrategias de orientación de la TLR en el tratamiento del cáncer.
- Analizar el potencial de los agonistas de TLR en la inmunoterapia contra el cáncer.
- Explorar los avances en los sistemas de administración terapéutica basados en TLR.
Principales métodos:
- Revisión sistemática de la literatura de patentes desde 2014 hasta 2024.
- Análisis de las estrategias de orientación de la TLR y sus efectos inmunomoduladores.
- Evaluación de los sistemas de administración de terapias contra el cáncer basadas en TLR.
Principales resultados:
- Los agonistas de TLR estimulan la inmunidad innata y adaptativa, lo que lleva a la muerte de las células tumorales.
- Las terapias TLR patentadas tienen como objetivo mejorar los tratamientos convencionales como la quimioterapia y la radioterapia.
- Los avances en los sistemas de administración (nanopartículas, liposomas) mejoran la orientación del agonista TLR y reducen la toxicidad.
Conclusiones:
- Las terapias basadas en TLR ofrecen un enfoque prometedor para la inmunoterapia del cáncer.
- Las terapias combinadas que involucran agonistas de TLR tienen potencial para mejorar los resultados de los pacientes.
- La investigación en curso aborda desafíos como los eventos adversos relacionados con el sistema inmunológico y la eficacia específica del tumor.
Palabras clave:
El cáncerTiempo de trabajoVacunas contra el cáncertratamiento combinadolas terapias dirigidasMás Videos Relacionados
Videos de Conceptos Relacionados
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
01:30Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K